| 1. |
|
|
| 2. |
- Momeni, H. R., et al.
(författare)
-
Apoptosis in cultured spinal cord slices of neonatal mouse
- 2008
-
Ingår i: Iranian Journal of Science and Technology Transaction A: Science. - 1028-6276. ; 32:A2, s. 109-116
-
Tidskriftsartikel (refereegranskat)abstract
- Organotypic spinal cord slices from neonatal mammals could be a powerful model for evaluation of cell survival but also cell death mechanisms. The aim of this study was to establish an in vitro model for investigating cell survival and mechanism involved in cell death in neonatal spinal cord slices. The spinal cord was sliced and incubated into culture medium. The MTT assay was carried out to assess the viability of the slices and fluorescent staining was used to study morphological features of apoptosis, where as nucleosomal DNA fragmentation was detected using agarose gel electrophoresis. The results of the present study demonstrated that the slices could be maintained in culture up to 14 days. Both neurons and glial cells died by apoptosis and application of a general caspase inhibitor neither affected slice survival nor nucleosomal DNA fragmentation after 24 h in culture. In addition, the inhibitor failed to block apoptosis in neurons and glial cells in the cultured slices. Our results suggest that in the cultured slices, apoptosis is the main reason for neuron and glial cell death, which occurs by a caspase-independent mechanism.
|
|
| 3. |
- Singh, A K, et al.
(författare)
-
CFTR and its key role in in vivo resting and luminal acid-induced duodenal HCO3-secretion
- 2008
-
Ingår i: Acta Physiologica. - : Wiley. - 1748-1708 .- 1748-1716. ; 193:4, s. 357-365
-
Tidskriftsartikel (refereegranskat)abstract
- Background and aims: We investigated the role of the recently discovered, villous-expressed anion exchanger Slc26a6 (PAT1) and the predominantly crypt-expressed cystic fibrosis transmembrane regulator (CFTR) in basal and acid-stimulated murine duodenal HCO3− secretion in vivo, and the influence of blood HCO3− concentration on both.Methods: The proximal duodenum of anaesthetized mice was perfused in situ, and HCO3− secretion was determined by back-titration. Duodenal mucosal permeability was assessed by determining 51Cr-EDTA leakage from blood to lumen.Results: Compared with wild type (WT) littermates basal duodenal HCO3− secretory rates were slightly reduced in Slc26-deficient mice at low (∼21 mm), and markedly reduced at high blood HCO3− concentration (∼29 mm). In contrast, basal HCO3− secretion was markedly reduced in CFTR-deficient mice compared with WT littermates both at high and low blood HCO3− concentration. A short-term application of luminal acid increased duodenal HCO3− secretory rate in Slc26a6-deficient and WT mice to the same degree, but had no stimulatory effect in the absence of CFTR. Luminal acidification to pH 2.5 did not alter duodenal permeability.Conclusions: The involvement of Slc26a6 in basal HCO3− secretion in murine duodenum in vivo is critically dependent on the systemic acid/base status, and this transporter is not involved in acid-stimulated HCO3− secretion. The presence of CFTR is essential for basal and acid-induced HCO3− secretion irrespective of acid/base status. This suggests a coupled action of Slc26a6 with CFTR for murine basal duodenal HCO3− secretion, but not acid-stimulated secretion, in vivo.
|
|
| 4. |
- Kharaziha, Pedram, et al.
(författare)
-
Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection : a phase I-II clinical trial
- 2009
-
Ingår i: European Journal of Gastroenterology and Hepathology. - 0954-691X .- 1473-5687. ; 21:10, s. 1199-1205
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: End-stage liver disease is a medical problem with high morbidity and mortality. We have investigated the feasibility, safety, and efficacy of using autologous mesenchymal stem cells (MSCs) as a treatment. METHODS: Eight patients (four hepatitis B, one hepatitis C, one alcoholic, and two cryptogenic) with end-stage liver disease having Model for End-Stage Liver Disease score > or =10 were included. Autologous MSCs were taken from iliac crest. Approximately, 30-50 million MSCs were proliferated and injected into peripheral or the portal vein. Liver function and clinical features were evaluated at baseline and 1, 2, 4, 8, and 24 weeks after injection. RESULTS: Treatment was well tolerated by all patients. Liver function improved as verified by the Model for End-Stage Liver Disease score, which decreased from 17.9±5.6 to 10.7±6.3 (P<0.05) and prothrombin complex from international normalized ratio 1.9±0.4 to 1.4±0.5 (P<0.05). Serum creatinine decreased from 114±35 to 80±18 µmol/l (P<0.05). Serum albumin changed from 30±5 to 33±5 g/l and bilirubin from 46±29 to 41±31 µmol/l. No adverse effects were noted. CONCLUSION: Our data show that MSCs injection can be used for the treatment of end-stage liver disease with satisfactory tolerability. Furthermore, this treatment may improve clinical indices of liver function in end-stage liver disease.
|
|
